最新发布

从管理气候风险到激活植物智慧,新朝阳ClimaBio™气候管理生物解决方案在巴西发布

大农化网报道:极端高温、持续干旱和降雨失序,正在让农业生产面对更高的不确定性。过去,农业主要通过品种改良、营养投入和病虫害防控提高生产效率。但面对越来越复杂的气候压力,仅依靠外部投入并不足够。如何调动植物自身的感知、防御和适应能力,正在成为…

July in review: L’Oréal lands Gucci Beauty, US FDA peptide decision, EU fragrance allergen deadline

Last month, in personal care industry news, L’Oréal announced plans to take over the 50-year exclusive global license agreement for Gucci Beauty, a year ahead of schedule. 

Estée Lauder and Puig keep fragrance ambitions alive after failed merger

Three months after the collapsed merger between Estée Lauder Companies (ELC) and Spanish beauty group Puig, both companies are focusing on fragrance to boost their respective beauty portfolios. 

Ukraine further delays EU-aligned cosmetic safety rules

The Ukrainian government has delayed fully implementing cosmetics regulations that would align the country’s cosmetic rules with EU standards. The new rules will now take effect on July 31, 2027, instead of the original date, today, August 3, 2026. The push back gives beauty businesses an extra year to prepare. 

Combined Phage Therapy and FMT Reduces Recurrent UTIs and Antibiotic Use in First Human Case Series

Recurrent urinary tract infections (rUTIs) are among the most common bacterial infections worldwide. The difficult-to-treat condition, which affects primarily women, is defined as two urinary tract infections (UTIs) within six months or three UTIs within the past year. They are a leading cause of outpatient antibiotic use, accounting for more than 15% of all prescriptions.

Micropep kickstarts global regulatory registration of its peptide-based biofungicide

France- and US-based ag biotech company Micropep is closer to commercializing its peptide-based biofungicide Promisin af…

科迪华2026上半年净销售额增至112.8亿美元:种子业务增长4%、植保增长3%

世界农化网中文网报道:7月31日,科迪华公布了截至2026年6月30日的第二季度及上半年财务业绩。得益于种子业务在最新需求旺盛的种质与性状技术方面的持续价值兑现(包括授权收入的增长),以及植保业务新产品需求与运营卓越的推动,公司上半年表现强劲,并据此上调了2026年全年业绩指引。同时,科迪华确认将于2026年10月1日如期完成分拆计划。

Ipsen quietly returns cancer drug IPN01194 to AGV Discovery

Why it matters: The decision removes one of Ipsen’s two experimental MAPK-pathway inhibitors for solid tumours and returns a clinical-stage programme to the small French biotech that discovered it.

Sobi’s dealmaker CEO exits for BioNTech

Why it matters: BioNTech’s decision provides a powerful external endorsement of Oelkers’ record at Sobi. Oelkers did not create Sobi’s scientific foundations, but he built a much larger commercial and dealmaking organization around them, expanding the company in the U.S. and adding a succession of acquired and licensed rare disease products. BioNTech is now hiring him for a similar company-building challenge: scaling an innovation-driven biotech as it prepares to launch multiple products.

Upstream Biotechnology raises seed funding for ‘on-demand’ crop defense tech

Plants already have the tools to respond to a range of biotic and abiotic threats. The problem, says North Carolina-base…